Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%

✍ Scribed by Merker, Ludwig; Lund, Soeren S.; Hantel, Stefan; Salsali, Afshin; Kim, Gabriel; Broedl, Uli; Woerle, Hans J.; Hach, Thomas

• Book ID: 127299049
• Publisher: Canadian Diabetes Association
• Year: 2014
• Tongue: English
• Weight: 107 KB
• Volume: 38
• Category: Article
• ISSN: 1499-2671
• DOI: 10.1016/j.jcjd.2014.07.159